Covid-19 put many businesses on hold, but not biotech. This sector is growing at record speeds, and only a small portion of the capital deals are related to the pandemic.
Seemingly in response to global uncertainty over the coronavirus outbreak, the stock markets have plunged, numerous conferences are being canceled and biopharma companies are taking action.
U.S. President Donald Trump will meet with Treasury Secretary Steven Mnuchin and other economic officials to weigh possible actions to stem the fallout from a widening coronavirus outbreak, an administration official told Reuters.
Shares of Johnson & Johnson tumbled 12 percent after Reuters reported that the pharma major knew for decades that cancer-causing asbestos lurked in the company’s Baby Powder.
After yesterday’s big plunge in the stock market, and today with the Dow Jones Industrial Average dropping more than 500 points after opening – but mostly recovering (so far) – volatility appears to be the key word to describe the stock market
U.S. Senate Republican leaders postponed a vote on a healthcare overhaul after resistance from members of their own party, and President Donald Trump summoned Republican senators to the White House to urge them to break the impasse.
Johnson & Johnson reported disappointing pharmaceutical and consumer product sales for first-quarter 2017 as revenue missed analyst estimates.